ReviewFrontiers in global women's health2022
Allopregnanolone in Postpartum Depression.
Review in Frontiers in global women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06759558 (Allopregnanolone), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Allopregnanolone (Zuranolone) in Post-stroke Depression
Who cites it
19 citing papers in PubMed, 39 citations in OpenAlex.
- The role of flower consumption in Howler Monkey Females' diet: adjustment across reproductive states.PeerJ · 2026Article
- Gestational stress disrupts the neuroimmune environment in the nucleus accumbens of maternal rats.Brain, behavior, & immunity - health · 2025Article
- Addressing the Global Mental Health Crisis: How a Human Rights Approach Can Help End the Search for Pharmaceutical Magic Bullets.Health and human rights · 2025Article
- The role of neuroactive steroids in psychiatric and neurological disorders: Neurobiology and therapeutic perspectives.Neuroscience and biobehavioral reviews · 2025Review
- Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical Practice.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Review
- Neuroactive Steroids as Novel Promising Drugs in Therapy of Postpartum Depression-Focus on Zuranolone.International journal of molecular sciences · 2025Review
- Allopregnanolone Concentrations After Ascending Single Dose Administration of Progesterone to Healthy Volunteers.Human psychopharmacology · 2025Article
- Neuroactive steroids in the programming of neurodevelopment: implications of maternal obesity.Frontiers in endocrinology · 2025Review
- Editorial: Molecular mechanisms in perinatal psychiatry.Frontiers in psychiatry · 2025Article
- Article
- Article
- Impact of premenstrual syndrome and premenstrual dysphoric disorder on maternal antenatal depression.PloS one · 2024Observational
- Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.European archives of psychiatry and clinical neuroscience · 2023Review
- Exploring Novel Therapeutic Approaches for Depressive Disorders: The Role of Allopregnanolone Agonists.Cureus · 2023Review
- The importance of translationally evaluating steroid hormone contributions to substance use.Frontiers in neuroendocrinology · 2023Review
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- GABAergic signaling in alcohol use disorder and withdrawal: pathological involvement and therapeutic potential.Frontiers in neural circuits · 2023Review
- Role of allopregnanolone-mediated γ-aminobutyric acid A receptor sensitivity in the pathogenesis of premenstrual dysphoric disorder: Toward precise targets for translational medicine and drug development.Frontiers in psychiatry · 2023Review
- (3α,5α)3-Hydroxypregnan-20-one (3α,5α-THP) Regulation of the HPA Axis in the Context of Different Stressors and Sex.Biomolecules · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum depression (PPD) is a debilitating psychiatric disorder characterized by a high worldwide prevalence and serious long-term negative outcomes for both mothers and children. The lack of a specific treatment and overreliance on pharmacotherapy with limited efficacy and delayed treatment response has constituted a complication in the management of PPD. Recently, the Food and Drug Administration (FDA) in the USA approved a synthetic formulation of the GABAergic neurosteroid allopregnanolone, administered intravenously (brexanolone) for the rapid, long-lasting and effective treatment of PPD. Hereinafter, we review findings on allopregnanolone biosynthesis and GABA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.